Compare FedEx Corporation (FDX) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? FedEx Corporation trades at $292.44 (market cap $69.04B), while Regeneron Pharmaceuticals Inc trades at $740.01 (market cap $76.14B). The key difference: FedEx Corporation and Regeneron Pharmaceuticals Inc are close in size by market cap, and FedEx Corporation pays the higher dividend (1.67%). Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| FDX | REGN | |
|---|---|---|
Market Cap | $69.04B | $76.14B |
Volume | 1,287,367 | 500,239 |
Sector | Industrials | Health |
52-Week High | $339.35 | $852.03 |
52-Week Low | $180.87 | $557.73 |
Typical Hold Time | 87 Days | 107 Days |
Enterprise Value | $98.68B | $70.85B |
Dividend Yield | 1.67% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FDX trades at $289.04, flat on the day, with a bearish technical signal from moving averages and ADX indicators. The company reported revenue of $87.93B for 2025, with a net income margin of 4.68% and a P/E ratio of 15.58. Recent news includes a $300 million order for electric trucks from Harbinger and shareholder approval of executive compensation at the annual meeting.
The outlook is mixed, with strong analyst buy consensus (57%) and a price target of $307.55 offering upside potential, but risks from rising fuel costs and a bearish technical trend suggest near-term volatility. Earnings beats in recent quarters support fundamental strength, yet macroeconomic pressures on logistics margins warrant caution.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
